PVLA

Insider trade Sale by Goin Kathleen (Chief Operating Officer)

10d ago

SEC filing PVLA Reports Positive Phase 3 SELVA and Phase 2 TOIVA Data for QTORIN Rapamycin, Showing 100% Improvement in Microcystic Lymphatic Malformations, 87% Reduction in Leaking/Bleeding Symptoms

12d ago

SEC filing PVLA Reports Phase 2 TOIVA: 100% Bleeding Improvement, +2.5 cVM-IGA Score in 4 Patients

18d ago

News Palvella targets 2H 2026 NDA filing while outlining >$1B peak U.S. sales potential for QTORIN rapamycin in microcystic lymphatic malformations

25d ago

Insider trade Sale by Kathleen Goin (Chief Operating Officer)

38d ago

Insider trade Sale by Kathleen Goin (Chief Operating Officer)

45d ago

SEC filing PVLA Adds Dr. John Doux to Board, Grants 6K Stock Option, Expands to 7 Directors

50d ago

News Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal

68d ago

Insider trade Sale by Kathleen Goin (Chief Operating Officer)

73d ago

News Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

92d ago

Insider trade Purchase by Elaine J Heron

92d ago

Insider trade Purchase by George M Jenkins

92d ago

Insider trade Sale by Kathleen Goin

104d ago

News Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

153d ago

Scanner Unusual volume (z=2.9)

160d ago

Scanner Unusual volume (z=3.1)

161d ago

Scanner Unusual volume (z=3.1)

163d ago

Scanner Unusual volume (z=3.1)

164d ago

Scanner Unusual volume (z=6.7)

168d ago